Doxorubicin loaded polymeric nanoparticulate delivery system to overcome drug resistance in osteosarcoma

BMC Cancer

Volumn 9, Issue , 2009, Pages

  Susa, Michiro ^a   Iyer, Arun K ^b,c   Ryu, Keinosuke ^a   Hornicek, Francis J ^a   Mankin, Henry ^a   Amiji, Mansoor M ^b   Duan, Zhenfeng ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NORTHEASTERN UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXTRANOMER; DOXORUBICIN; GLYCOPROTEIN P; MACROGOL; NANOPARTICLE; ANTINEOPLASTIC AGENT; DEXTRAN; DRUG CARRIER; POLYMER;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOCOMPATIBILITY; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG EFFICACY; DRUG RETENTION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MULTIDRUG RESISTANCE; NANOPHARMACEUTICS; OSTEOSARCOMA; PROTEIN EXPRESSION; SUSTAINED RELEASE FORMULATION; BONE TUMOR; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG RESISTANCE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; METHODOLOGY; TUMOR CELL LINE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; BONE NEOPLASMS; CELL LINE, TUMOR; DEXTRANS; DOXORUBICIN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; HUMANS; MICROSCOPY, FLUORESCENCE; NANOPARTICLES; OSTEOSARCOMA; POLYMERS;

EID: 71949105972     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-9-399     Document Type: Article

References (45)

1. Fletcher C, Unni K, Mertens F, . eds Pathology and Genetics of Tumours of Soft Tissue and Bone 2002, Lyon: IARC Press.
2. Schwartz CL, Gorlick R, Teot L, Krailo M, Chen Z, Goorin A, Grier HE, Bernstein ML, Meyers P, . Children's Oncology Group Multiple drug resistance in osteogenic sarcoma: INT0133 from the Children's Oncology Group. J Clin Oncol 2007, 25(15):2057-62. 10.1200/JCO.2006.07.7776, 17513810.
3. Chou AJ, Gorlick R. Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther 2006, 6(7):1075-85. 10.1586/14737140.6.7.1075, 16831079.
4. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005, 5:275-284. 10.1038/nrc1590, 15803154.
5. Mimeault M, Hauke R, Baktra SK. Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies. Clin Pharmacol Ther 2008, 83(5):673-91. 10.1038/sj.clpt.6100296, 17786164.
6. Lourda M, Trougakos IP, Gonos ES. Development of resistance to chemotherapeutic drugs in human osteosarcoma cell lines largely depends on up-regulation of Clusterin/Apolipoprotein J. Int J Cancer 2007, 120(3):611-22. 10.1002/ijc.22327, 17096323.
7. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006, 5:219-234. 10.1038/nrd1984, 16518375.
8. Kaye SB. Reversal of drug resistance in ovarian cancer: where do we go from here?. J Clin Oncol 2008, 26:2616-2618. 10.1200/JCO.2008.16.2123, 18509172.
9. Sikic BI. Pharmacologic approaches to reversing multidrug resistance. Semin Hematol 1997, 34:40-47.
10. Shen YC, Chou CJ, Chiou WF, Chen CF. Anti-inflammatory effects of the partially purified extract of radix Stephaniae tetrandrae: comparative studies of its active principles tetrandrine and fangchinoline on human polymorphonuclear leukocyte functions. Mol Pharmacol 2001, 60:1083-1090.
11. Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 2000, 11:265-283. 10.1016/S0928-0987(00)00114-7, 11033070.
12. Twentyman PR, Bleehen NM. Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin [corrected]. Eur J Cancer 1991, 27:1639-1642. 10.1016/0277-5379(91)90435-G, 1816768.
13. Kolitz JE, George SL, Dodge RK, Hurd DD, Powell BL, Allen SL, Velez-Garcia E, Moore JO, Shea TC, Hoke E, Caligiuri MA, Vardiman JW, Bloomfield CD, Larson RA. Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621. J Clin Oncol 2004, 22:4290-4301. 10.1200/JCO.2004.11.106, 15514371.
14. Sonneveld P, Suciu S, Weijermans P, Beksac M, Neuwirtova R, Solbu G, Lokhorst H, Lelie J, Dohner H, Gerhartz H, Segeren CM, Willemze R, Lowenberg B. Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914). Br J Haematol 2001, 115:895-902. 10.1046/j.1365-2141.2001.03171.x, 11843823.
15. Page R, Takimoto C. Cancer management: a multidisciplinary approach: medical, surgical, and radiation oncology. Principles of chemotherapy 2004, 21-38. New York: PRP, Pazdur R, 8.
16. Sahoo SK, Labhasetwar V. Enhanced antiproliferative activity of transferrin- conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. Mol Pharm 2005, 2:373-83. 10.1021/mp050032z, 16196490.
17. van Vlerken LE, Vyas TK, Amiji MM. Poly (ethylene glycol) - modified Nanocarriers for Tumor - targeted and Intracellular Delivery. Pharmaceutical research 2007, 24(8):1405-13. 10.1007/s11095-007-9284-6, 17393074.
18. Hoste K, Bruneel D, De Marre A, De Schrijver F, Schacht E. Synthesis and characterization of poly(oxyethylene) modified dextrans. Macromol Rapid Commun 1994, 15(9):697-704.
19. Franssen O, Van Ooijen RD, De Boer D, Maes RAA, Herron JN, Hennink WE. Enzymatic Degradation of Methacrylated Dextrans. Macromolecules 1997, 30(24):7408-13.
20. Berrada S, Amedee J, Avramoglou T, Jozefonvicz J, Harmand MF. Effect of a derivatized dextran on human osteoblast growth and phenotype expression. J Biomater Sci Polymer Ed 1995, 6(2):211-222.
21. Bernstein A, Hurwitz E, Maron R, Arnon R, Sela M, Wilchek M. Higher antitumor efficacy of daunomycin when linked to dextran: in vivo and in vitro studies. J Natl Cancer Inst 1978, 60(2):379-84.
22. Zhang Y, Won CY, Chu CC. Synthesis and characterization of biodegradable network hydrogels having both hydrophobic and hydrophilic components with controlled swelling behavior. J Polym Sci Part A: Polym Chem 2003, 41:386-394.
23. Martwiset S, Koh AE, Chen W. Nonfouling characteristics of dextran -containing surfaces. Langmuir 2006, 22(19):8192-6. 10.1021/la061064b, 2505053, 16952261.
24. Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys 1959, 82(1):70-7. 10.1016/0003-9861(59)90090-6, 13650640.
25. Krishan A, Sauerteig A, Wellham LL. Flow Cytometric Studies on Modulation of Cellular Adriamycin Retention by Phenothiazines. Cancer Res 1985, 45:1046-1051.
26. Venne A, Li S, Mandeville R, Kabanov A, Alakhov V. Hypersensitizing Effect of Pluronic L61 on Cytotoxic Activity, Transport, and Subcellular Distribution of Doxorubicin in Multiple Drug-resistant Cells. Cancer Res 1996, 56:3626-3629.
27. Otsuka H, Nagasaki Y, Kataoka K. PEGylated nanoparticles for biological and pharmaceutical applications. Adv Drug Deliv Rev 2003, 55(3):403-19. 10.1016/S0169-409X(02)00226-0, 12628324.
28. Lukyanov AN, Torchilin VP. Micelles from lipid derivatives of water-soluble polymers as delivery systems for poorly soluble drugs. Adv Drug Deliv Rev 2004, 56(9):1273-89. 10.1016/j.addr.2003.12.004, 15109769.
29. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res 1986, 46:6387-6392.
30. Noguchi Y, Wu J, Duncan R, Strohalm J, Ulbrich K, Akaike T, Maeda H. Early phase tumor accumulation of macromolecules: A great difference in clearance rate between tumor and normal tissues. Jpn J Cancer Res 1998, 89:307-314.
31. Minko T, Kopecková P, Kopecek J. Efficacy of the chemotherapeutic action of HPMA copolymer- bound doxorubicin in a solid tumor model of ovarian carcinoma. Int J Cancer 2000, 86(1):108-17. 10.1002/(SICI)1097-0215(20000401)86:1<108::AID-IJC17>3.0.CO;2-8, 10728603.
32. Broxterman HJ, Schuurhuis GJ, Lankelma J, Baak JPA, Pinedo HM. Towards functional screening for multidrug resistant cells in human malignancies. Pezcoller Foundation Symphosia1. Drug Resistance: Mechanisms and Reversal 1990, 309-319. Rome: John Libbey CIC, Mihich E.
33. Hindenburg AA, Baker MA, Gleyzer E, Stewart VJ, Case N, Taub RN. Effect of verapamil and other agents on the distribution of anthracyclines and on reversal of drug resistance. Cancer Res 1987, 47:1421-1425.
34. Keizer HG, Schuurhuis GJ, Broxterman HJ, Lankelma J, Schoonen WG, van Rijn J, Pinedo HM, Joenje H. Correlation of multidrug resistance with decreased drug accumulation, altered subcellular drug distribution, and increased P-glycoprotein expression in cultured SW-1573 human lung tumor cells. Cancer Res 1989, 49:2988-2993.
35. Schuurhuis GJ, Broxterman HJ, Cervantes A, van Heijningen TH, de Lanee JHM, Baak JPA, Pinedo HM, Lankelma J. Quantitative determination of factors contributing to doxorubicin resistance in multidrug-resistant cells. J Natl Cancer Inst 1989, 81:1887-1892. 10.1093/jnci/81.24.1887, 2574239.
36. Willingham MC, Cornwell MM, Cardarelli CO, Gottesmann MM, Pastan I. Single cell analysis of daunomycin uptake and efflux in multidrug-resistant and -sensitive KB cells: Effects of verapamil and other drugs. Cancer Res 1986, 46:5941-5946.
37. Jiang Z, Chen BA, Xia GH, Wu Q, Zhang Y, Hong TY, Zhang W, Cheng J, Gao F, Liu LJ, Li XM, Wang XM. The reversal effect of magnetic Fe3O4 nanoparticles loaded with cisplatin on SKOV3/DDP ovarian carcinoma cells. Int J Nanomedicine 2009, 4:107-14. 2720746, 19516889.
38. Chen BA, Dai YY, Wang XM, Zhang RY, Xu WL, Shen HL, Gao F, Sun Q, Deng XJ, Ding JH, Gao C, Sun YY, Cheng J, Wang J, Zhao G, Chen NN. Synergistic effect of the combination of nanoparticulate Fe3O4 and Au with daunomycin on K562/A02 cells. Int J Nanomedicine 2008, 3(3):343-50. 10.2217/17435889.3.3.343, 2626936, 18990943.
39. Kantharidis P, El-Osta A, deSilva M, Wall DM, Hu XF, Slater A, Nadalin G, Parkin JD, Zalcberg JR. Altered methylation of the human MDR 1 promoter is associated with acquired multidrug resistance. Clin Cancer Res 1997, 3:2025-2032.
40. Jin S, Scotto KW. Transcriptional regulation of the MDR 1 gene by histone acetyltransferase and deacetylase is mediated by NF - Y. Mol Cell Biol 1998, 18:4377-4384. 109021, 9632821.
41. Nakayama M, Wada M, Harada T, Nagayama J, Kusaba H, Ohshima K, Kozuru M, Komatsu H, Ueda R, Kuwano M. Hypomethylation status of CpG sites at the promoter region and overexpression of the human MDR 1 gene in acute myeloid leukemias. Blood 1998, 92:4296-4307.
42. El-Osta A, Kantharidis P, Zalcberg JR, Wolffe AP. Precipitous release of methyl - CpG binding protein 2 and histone deacetylase 1 from the methylated human multidrug resistance gene (MDR 1) on activation. Mol Cell Biol 2002, 22:1844-1857. 10.1128/MCB.22.6.1844-1857.2002, 135609, 11865062.
43. Duncan R, Kopeckova-Rejmanova P, Strohalm J, Hume I, Cable HC, Pohl J, Lloyd JB, Kopecek J. Anticancer agents coupled to [N-(2 hydroxypropyl)methacrylamide] copolymers. 1. Evaluation of daunomycin and puromycin conjugates in vitro. Br J Cancer 1987, 55:165-174. 2002078, 3468994.
44. Minko T, Kopeckova P, Kopecek J. Mechanisms of anticancer action of HPMA copolymer-bound doxorubicin. Macromol Symp 2001, 172:35-37.
45. Miettinena S, Gre'nmand S, Ylikomia T. Inhibition of P-glycoprotein-mediated docetaxel efflux sensitizes ovarian cancer cells to concomitant docetaxel and SN-38 exposure. Anti-Cancer Drugs 2009, 20:267-276. 10.1097/CAD.0b013e328329977f, 19262372.